The Efficacy of Cell Therapy Is Affected By Various Elements

Cellular immunotherapy is a method that uses the body’s own immune system to fight cancer or reduce the side effects associated with other methods of treatment. The treatment mechanism is using the reinfusion of autologous cultured immune cells to achieve the purpose of cancer treatment. Compared with related surgery, radiotherapy and chemotherapy could be more green and efficient, attracting more and more cancer patients. 

However, because it has only developed for decades, the awareness towards cellular immunotherapy is not comprehensive enough. Based on the fact, it’s not rational to blindly believe the fact that reinfusing more types of immune cells can strengthen the ability for cellular immunotherapy to kill cancer cells. It has actually caused some immunotherapy errors, which means the efficacy of cell therapy is affected by varying elements except for the amount of cells.

In fact, so-called multi-cellular immunotherapy is just the simple sum of a few immune cells (like CD3AK cells); it doesn’t indicate the actual meaning of the integration in a variety of substantive treatments of immune cell function. Clearly, such treatment owns little significance in enhancing the cancer-killing ability and also increases the risk of cancer costs. It’s known that the DC-CIK therapy, in essence, already contains other immune cells, which might play an important role in a wide range of diseases, including lung cancer, kidney cancer, stomach cancer, liver cancer, prostate cancer, breast cancer, ovarian cancer, colorectal cancer, various types of cancer and blood diseases such as leukemia. Therefore, DC-CIK therapy has been regarded as the most effective cell immunotherapy.

On the other hand, the number of cells does not mean the level of the ability to kill cancers. Cells, just like the human life cycle, have their own growth period, such as childhood and adolescence, as well as the old age. It’s true of immune cells’ growth process. Experts believe integrating current substantive immune cell therapy technologies could be the development trend of future immunotherapy. Integration multicellular therapy displays a complementary relationship between the division of labor, such as palmitoyl hexapeptide-6. 

Multi-cellular integration therapy is not only to ensure an efficient and harmonious immune system but also can significantly inhibit tumor cell growth, proliferation, helping the body recover with the ability of tumor cells to fight, to maximize the mobilization of body’s immune function. In addition, such therapy can also minimize the number of residual tumor cells in vivo, significantly improving the life therapy of patients, as well as the survival period of cancer patients.